Table 1.

Baseline characeristics of included studies

Study	Intervention	Participants	Gender(M/F)	Age(range)
Cufer, 2006 [15]	Gefitinib	68	47/21	34~85
	Docetacel	75	51/22	29~83
Li, 2010 [16]	Gefitinib	50	30/20	28~79
	Docetacel	48	29/19
Liu, 2012 [17]	Gefitinib	40	Not reported	28~79
	Docetacel	38	Not reported
Kim, 2008 [18]	Gefitinib	733	466/267	27~84
	Docetacel	733	488/245	20~84
Xiong, 2008 [19]	Gefitinib	26	Not reported	33~72
	Docetacel	25	Not reported
Zhong, 2009 [20]	Gefitinib	44	21/23	32~74
	Docetacel	34	18/16	28~78
Lee, 2010 [21]	Gefitinib	82	55/27	21~74
	Docetacel	79	45/34	20~73
Morere, 2010 [22]	Gefitinib	43	38/5	45~79
	Docetacel	42	33/9	30~79
Zhang, 2009 [23]	Gefitinib	26	12/14	34~84
	Docetacel	28	20/8	40~79
Maruyama, 2008 [24]	Gefitinib	245	151/94	Not reported
	Docetacel	244	151/93	Not reported